Results 21 to 30 of about 159,964 (350)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer

Cancers, 2021
Simple Summary Over the last decade, immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) have dramatically changed the therapeutic algorithm of several ...
A. Rizzo, A. Ricci, G. Brandi
semanticscholar   +1 more source

Promising Genomic Testing for Biliary Tract Cancer Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration/Biopsy Specimens

Diagnostics, 2022
The undesired prognosis of biliary tract cancer is mainly attributed to the difficult detection of cancer lesions, including intraepithelial neoplasia and no standard examination for screening.
Masaki Kuwatani, Kazumichi Kawakubo, Naoya Sakamoto   +2 more
doaj   +1 more source

N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes

iScience, 2023
Summary: CircRNAs play multiple roles in a variety of cellular processes. We found that Circ-CDYL is highly enriched in early HCC plasma exosomes. Moreover, EpCAM+ HCC cells and exosomes had significant Circ-CDYL levels.
Yanping Wei, Jingbo Fu, Hailing Zhang, Yan Ling, Xuewu Tang, Shuowu Liu, Miao Yu, Fuyan Liu, Guokun Zhuang, Haihua Qian, Kecheng Zhang, Pinhua Yang, Xinwei Yang, Qi Yang, Shennian Ge, Baohua Zhang, Yexiong Tan, Liang Li, Hongyang Wang   +18 more
doaj   +1 more source

Interplay between the Human Microbiome and Biliary Tract Cancer: Implications for Pathogenesis and Therapy

Microorganisms, 2023
Biliary tract cancer, encompassing intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder carcinoma, stands as a prevalent malignancy characterized by escalating incidence rates and unfavorable prognoses.
Cheng Ye, Chunlu Dong, Yanyan Lin, Huaqing Shi, Wence Zhou   +4 more
doaj   +1 more source

Gut Microbiota in Diagnosis, Therapy and Prognosis of Cholangiocarcinoma and Gallbladder Carcinoma—A Scoping Review

Microorganisms, 2023
Cancers of the biliary tract are more common in Asia than in Europe, but are highly lethal due to delayed diagnosis and aggressive tumor biology. Since the biliary tract is in direct contact with the gut via the enterohepatic circulation, this suggests a
Ann-Kathrin Lederer, Hannah Rasel, Eva Kohnert, Clemens Kreutz, Roman Huber, Mohamed Tarek Badr, Patricia K. E. Dellweg, Fabian Bartsch, Hauke Lang   +8 more
doaj   +1 more source

Precision Oncology Targets in Biliary Tract Cancer

Cancers, 2023
Simple Summary Biliary tract cancer is rare in the US but remains a highly lethal cancer. While the standard of care in the first-line, metastatic setting is well-established, no second-line regimen has been clearly defined as the gold standard.
N. Farha, D. Dima, F. Ullah, Suneel D. Kamath   +3 more
semanticscholar   +1 more source

Durvalumab: A Review in Advanced Biliary Tract Cancer

Targeted oncology, 2023
Biliary tract cancers are a diverse group of cancers that develop in the bile ducts or the gallbladder. Patients with these cancers typically have poor survival.
Simon Fung, Yahiya Y. Syed
semanticscholar   +1 more source

16S rDNA microbiome composition pattern analysis as a diagnostic biomarker for biliary tract cancer

World Journal of Surgical Oncology, 2020
Background The aim of this study is to investigate the composition of microbiota in biliary tract cancer patients and healthy adults by metagenome analysis and evaluate its potential values as biomarkers for biliary tract cancer.
Huisong Lee, Hyeon Kook Lee, Seog Ki Min, Won Hee Lee   +3 more
doaj   +1 more source

Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.

Future Oncology, 2022
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of a humanized monoclonal anti-HER2 antibody, a cleavable tetrapeptide-based linker and a potent topoisomerase I inhibitor.
A. Ohba, C. Morizane, M. Ueno, Satoshi Kobayashi, Y. Kawamoto, Y. Komatsu, M. Ikeda, Mitsuhito Sasaki, N. Okano, J. Furuse, N. Hiraoka, Hiroshi Yoshida, A. Kuchiba, R. Sadachi, Kenichi Nakamura, N. Matsui, Y. Nakamura, W. Okamoto, T. Yoshino, T. Okusaka   +19 more
semanticscholar   +1 more source

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

JCO Precision Oncology, 2022
PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and molecularly defined subsets of BTC may improve patient selection for immunotherapy and inform ...
K. Mody, Prerna Jain, S. El-Refai, N. Azad, Daniel J. Zabransky, M. Baretti, R. Shroff, R. Kelley, Anthony B El-Khouiery, A. Hockenberry, D. Lau, G. Lesinski, M. Yarchoan   +12 more
semanticscholar   +1 more source